Selective review and commentary on emerging pharmacotherapies for opioid addiction

Pharmacotherapies for opioid addiction under active development in the US include lofexidine (primarily for managing withdrawal symptoms) and Probuphine®, a distinctive mode of delivering buprenorphine for six months, thus relieving patients, clinicians, and regulatory personnel from most concerns a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Walter, Mooney, Larissa, Zhao, Min, Nielsen, Suzanne, Torrington, Matthew, Miotto, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846315/
https://www.ncbi.nlm.nih.gov/pubmed/24474855
http://dx.doi.org/10.2147/SAR.S22782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846315/
https://www.ncbi.nlm.nih.gov/pubmed/24474855
http://dx.doi.org/10.2147/SAR.S22782

Ejemplares similares